AR040222A1 - Sales farmaceuticas de reboxetina - Google Patents
Sales farmaceuticas de reboxetinaInfo
- Publication number
- AR040222A1 AR040222A1 ARP030102115A ARP030102115A AR040222A1 AR 040222 A1 AR040222 A1 AR 040222A1 AR P030102115 A ARP030102115 A AR P030102115A AR P030102115 A ARP030102115 A AR P030102115A AR 040222 A1 AR040222 A1 AR 040222A1
- Authority
- AR
- Argentina
- Prior art keywords
- reboxetine
- pharmaceutical salts
- enantiomer
- fumarate
- salts
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title abstract 2
- 229960003770 reboxetine Drugs 0.000 title abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 150000003890 succinate salts Chemical class 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- CBQGYUDMJHNJBX-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1OC(C=1C=CC=CC=1)C1OCCNC1 CBQGYUDMJHNJBX-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008196 pharmacological composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077366 | 2002-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040222A1 true AR040222A1 (es) | 2005-03-16 |
Family
ID=29724495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102115A AR040222A1 (es) | 2002-06-17 | 2003-06-13 | Sales farmaceuticas de reboxetina |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20070010517A1 (https=) |
| EP (1) | EP1515959B1 (https=) |
| JP (1) | JP4563172B2 (https=) |
| KR (1) | KR100779786B1 (https=) |
| CN (2) | CN101298440A (https=) |
| AR (1) | AR040222A1 (https=) |
| AT (1) | ATE439354T1 (https=) |
| AU (1) | AU2003227755B2 (https=) |
| BR (1) | BR0311878A (https=) |
| CA (1) | CA2489763C (https=) |
| DE (1) | DE60328787D1 (https=) |
| DK (1) | DK1515959T3 (https=) |
| ES (1) | ES2328472T3 (https=) |
| MX (1) | MXPA04011916A (https=) |
| MY (1) | MY131231A (https=) |
| NO (1) | NO329346B1 (https=) |
| NZ (1) | NZ537023A (https=) |
| PE (1) | PE20040565A1 (https=) |
| PL (1) | PL375211A1 (https=) |
| RU (1) | RU2286341C2 (https=) |
| TW (1) | TWI267510B (https=) |
| WO (1) | WO2003106441A1 (https=) |
| ZA (1) | ZA200409624B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319793D0 (en) * | 2003-08-22 | 2003-09-24 | Lilly Co Eli | Pyridinylmorpholine derivatives |
| WO2005082869A1 (en) * | 2004-02-20 | 2005-09-09 | Pharmacia & Upjohn Company Llc | Method for the preparation of aryl ethers |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| WO2018106825A1 (en) * | 2016-12-06 | 2018-06-14 | Tonix Pharmaceuticals Holding Corp. | Salts and polymorphs of esreboxetine |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2167407B (en) * | 1984-11-22 | 1988-05-11 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
| AU9214498A (en) * | 1997-09-23 | 1999-04-12 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
| UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
| IT1305322B1 (it) * | 1998-04-23 | 2001-05-04 | Pharmacia & Upjohn Spa | Uso di reboxetina per il trattamento di disturbi nervosi |
| DE60022692T2 (de) * | 1999-07-01 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen |
-
2003
- 2003-06-04 US US10/588,808 patent/US20070010517A1/en not_active Abandoned
- 2003-06-04 DE DE60328787T patent/DE60328787D1/de not_active Expired - Lifetime
- 2003-06-04 WO PCT/EP2003/005261 patent/WO2003106441A1/en not_active Ceased
- 2003-06-04 PL PL03375211A patent/PL375211A1/xx not_active Application Discontinuation
- 2003-06-04 RU RU2005100846/04A patent/RU2286341C2/ru not_active IP Right Cessation
- 2003-06-04 KR KR1020047020412A patent/KR100779786B1/ko not_active Expired - Fee Related
- 2003-06-04 NZ NZ537023A patent/NZ537023A/en unknown
- 2003-06-04 CA CA002489763A patent/CA2489763C/en not_active Expired - Fee Related
- 2003-06-04 MX MXPA04011916A patent/MXPA04011916A/es active IP Right Grant
- 2003-06-04 BR BR0311878-9A patent/BR0311878A/pt not_active IP Right Cessation
- 2003-06-04 DK DK03725195T patent/DK1515959T3/da active
- 2003-06-04 EP EP03725195A patent/EP1515959B1/en not_active Expired - Lifetime
- 2003-06-04 CN CNA200810093308XA patent/CN101298440A/zh active Pending
- 2003-06-04 CN CN038139839A patent/CN1662511B/zh not_active Expired - Fee Related
- 2003-06-04 AU AU2003227755A patent/AU2003227755B2/en not_active Ceased
- 2003-06-04 AT AT03725195T patent/ATE439354T1/de not_active IP Right Cessation
- 2003-06-04 ES ES03725195T patent/ES2328472T3/es not_active Expired - Lifetime
- 2003-06-04 JP JP2004513273A patent/JP4563172B2/ja not_active Expired - Fee Related
- 2003-06-11 TW TW092115889A patent/TWI267510B/zh not_active IP Right Cessation
- 2003-06-11 MY MYPI20032183A patent/MY131231A/en unknown
- 2003-06-13 AR ARP030102115A patent/AR040222A1/es unknown
- 2003-06-17 PE PE2003000594A patent/PE20040565A1/es not_active Application Discontinuation
-
2004
- 2004-11-29 ZA ZA200409624A patent/ZA200409624B/xx unknown
-
2005
- 2005-01-12 NO NO20050183A patent/NO329346B1/no not_active IP Right Cessation
-
2009
- 2009-05-21 US US12/469,780 patent/US20090291953A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27940A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a | |
| ECSP066365A (es) | Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk | |
| ECSP045491A (es) | Nueva sal formiato de o-desmetil venlafaxina | |
| CL2003002767A1 (es) | Composicion oral que comprende una pelicula que contiene un material funcional, en un vehiculo, util para el cuidado oral. | |
| PE20020722A1 (es) | Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano | |
| ECSP034436A (es) | Sales de valsartan | |
| EA200200117A1 (ru) | Применение ингибиторов моноаминоксидазы для производства лекарств, предназначенных для лечения ожирения | |
| ECSP024352A (es) | Nueva composicion farmaceutica | |
| UY27175A1 (es) | Nueva sal succinato de o-desmetil- venlafaxina | |
| MX9700358A (es) | Proceso par a la sintesis de sulfoxidos substituidos. | |
| GT200200272A (es) | Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino] quinazolin-6-il} alil)acetamidayprocedimiento para la produccion | |
| BR0301073A (pt) | Polpa fofa branqueada, método de fabricação da mesma, produto absorvente de cuidado pessoal, e, artigo absorvente | |
| AR003476A1 (es) | Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol | |
| ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| UY25108A1 (es) | Modificación termodinámicamente estable de 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, procedimiento para su preparación y composiciones farmacéuticas que lo contienen. | |
| DE59608698D1 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
| ATE332894T1 (de) | Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe | |
| AR040222A1 (es) | Sales farmaceuticas de reboxetina | |
| BRPI0408689A (pt) | derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor | |
| ATE427737T1 (de) | Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen | |
| TR200101970T2 (tr) | Solunum yollarì hastalìklarìnìn tedavisinde matriks metaloproteaz inhibitrleri olarak ikameli 4-biarilbutirik ve 5-biarilpentanoik asit trevlerinin kullanìlmasì | |
| BRPI0414781A (pt) | aminoácidos com afinidade para a proteìna (alfa)2(delta) | |
| PE20020845A1 (es) | Derivados de o -amino-n-hidroxi-acetamida | |
| BR9911679A (pt) | Sais de paroxetina | |
| AR006281A1 (es) | Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |